Contact Us

Have questions? 

Please email us at casl@hepatology.ca or call us at 780-436-0983 ext.234

           

123 Street Avenue, City Town, 99999

(123) 555-6789

email@address.com

 

You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.

Program

PRELIMINARY PROGRAM-AT-A-GLANCE

FRIDAY, FEBRUARY 9, 2018
7th Canadian Symposium on Hepatitis c

WITH Canadian Liver Meeting Opening EVENING Reception & KEYNOTE SPEAKER

    MEETING ROOM
     
7:15 - 8:00 am Registration Open
BALLROOM FOYER
     
8:00 - 8:15 am
 
Welcome & Introductions
Naglaa Shoukry, Université de Montréal
BALLROOM A & B
 
 
8:15 - 9:50 am Session #1: Biomedical Research
BALLROOM A & B
  Co-Chairs: Mohamed Abdel-Hakeem & Sonya MacParland  

8:15 - 8:35 am Reinfection with Hepatitis C Virus - T Cells to the Rescue?
  Georg Lauer, Harvard University Boston
   
8:35 - 8:55 am DAA-induced Reversal of Immune Senescence
  Lisa Barrett, Dalhousie University
   
8:55 - 9:15 am Questions and Panel Discussion
   
9:15 - 9:27 am
 
miR-122 Does Not Impact Recognition of the HCV Genome by Innate Sensors of RNA but Rather Protects the 5’ End from the Cellular Triphosphatases, DOM3Z and DUSP11
  Annie Bernier, McGill University
   
9:27 - 9:39 am Increased Usage of a Public CD8 T Cell Clonotype in Spontaneously Resolved HCV Infection
  Lisa Barrett, Dalhousie University
   
9:39 - 9:51 am
 
Impaired CD8+ T-cell Function is Associated with Liver Disease Severity in Chronic HCV Infection and Remains Unresolved After HCV Cure
  Angela Crawley, Ottawa Hospital Research Institute
    MEETING ROOM
     
9:50 - 10:10 am Coffee Break
ONTARIO/NIAGARA
 
10:10 - 11:45 am Session #2: Social, Cultural, Environmental and Population Health Research
BALLROOM A & B
  Co-Chairs: Didier Jutras-Aswad & Alexandra King  
10:10 - 10:30 am A People-Centered Health Systems Approach to Hepatitis Elimination
  Jeffrey Lazarus, University of Barcelona
   
10:30 - 10:50 am Indigenous Data Sovereignty on the Path to HCV Elimination
  Jennifer Walker, Laurentian University
   
10:50 - 11:02 am Nothing About Us Without Us: the value of engaging people with lived experience of HCV in all areas of the HCV response
  Lindsay Jennings, Shujeet Husein & Suzanne Fish, CATIE
   
11:02 - 11:22 am Questions & Panel Discussion
   
11:22 - 11:34 am HCV: Bringing Care to Patients in Rural and Remote Settings
  Dustin Dapp & Lucy Newman-Hogan, Simon Fraser University
   
11:34 - 11:45 am Ontario Hepatitis C Education and Outreach Program with Immigrants and Newcomers
  Fozia Tanveer, CATIE, Canada
    MEETING ROOM
     
11:45 am - 1:30 pm Lunch & Poster Sessions
ONTARIO/NIAGARA
     
1:30 - 3:05 pm Session #3: Clinical Resesarch
BALLROOM A & B
  Co-Chairs: Valerie Martel-Laferriere & Giada Sebastiani  
1:30 - 1:50 pm NK Cell and T Cell Function During and After HCV
  Heiner Wedemeyer, Hanover Medical School
   
1:50 - 2:10 pm HCV Policy in Action: Lessons learned from Portugal
  Ricardo Baptista Leite, Member of Parliament, Lisbon, Portugal
   
2:10 - 2:30 pm Questions & Panel Discussion
   
2:30 pm - 2:42 pm Real-world Effectiveness of Interferon-free, All-oral Direct-acting Antivirals in the Setting of Hepatitis C and HIV Co-infection
  Carmine Rossi, Research Institute of the McGill University Health Centre
   
2:42 - 2:54 pm All-Oral Anti-HCV Therapy in Injection Drug Users: Updated Real World Data
  Arshia Alimohammadi, Vancouver Infectious Diseases Centre
   
2:54 - 3:05 pm Decreased Hepatitis C (HCV) Treatment Uptake Among HIV-HCV Co-Infected Patients with a History of Incarceration: Missed Opportunities for Care
  Nadine Kronfli, McGill University Health Centre
    MEETING ROOM
     
3:05 - 3:20 pm Coffee Break
ONTARIO/NIAGARA
     
3:20 - 5:05 pm Session #4: Health Services Research
BALLROOM A & B
  Co-Chairs: Brian Conway & Maryam Darvishian  
3:20 - 3:40 pm Use of Data to Drive Global Policy to Eliminate HCV
  Homie Razavi, Centre for Disease Analysis
   
3:40 - 4:00 pm What is Needed to Eliminate Hepatitis C in Canada?
  Naveed Janjua, University of British Columbia
   
4:00 - 4:20 pm Questions & Panel Discussion
   
4:20 - 4:42 pm
 
Decreased Confirmation of Chronic Hepatitis C Infections in Correctional Institutions Compared to the Community in Ontario
  Nagma Grewal, Queen's University
   
4:42 - 4:54 pm Estimation of Hepatitis C Prevalence in Canada Via a Two-Stage Back-Calculation Algorithm
  Abdullah Hamadeh, University of Waterloo
   
4:54 - 5:05 pm
 
Population-Level Cascade of Care for Hepatitis C in British Columbia: Differences over time, by gender and birth cohort
  Nuria Chapinal, BC Centre for Disease Control
    MEETING ROOM
     
5:05 - 5:20 pm Break
ONTARIO/NIAGARA
     
5:20 - 6:30 pm

CANADIAN LIVER MEETING & KEYNOTE SPEAKER

BALLROOM A & B
5:20 - 5:30 pm Introduction of the Canadian Liver Meeting
  Jordan Feld & Rick Schreiber
   
5:30 - 6:00 pm Healthy Policy Talk and Panel Discussion
  Alison Marshall, CanHepC Trainee Canada
   
6:00 - 6:20 pm A Framework for a National Hepatitis C Elimination Strategy in Canada
  Speaker TBC
   
6:20 - 6:30 pm 7th Canadian Symposium on Hepatitis C Closing Remarks
  Jordan Feld, Toronto General Hospital Research Institute
    MEETING ROOM
     
6:30 - 7:30 pm Canadian Liver Meeting Opening Reception
ONTARIO/NIAGARA
     

SATURDAY, FEBRUARY 10, 2018
CANADIAN LIVER MEETING

BREAKFAST SYMPOSIA
Please note: an additional fee is required for the Breakfast Symposia

    MEETING ROOM
     
7:00 - 4:00 pm Registration Open
BALLROOM FOYER
TIME
Tips Optimizing Outcomes
GRENADIER ROOM
Reducing Hospital
Admission in Cirrhosis
KINGSWAY ROOM

Pathophysiology
of Hepatic Encephalopathy
HALIBURTON ROOM
7:00 - 7:45 am
 
 
 
 
 
 
 
 
 
 

Speaker: Juan Gonzalez-Abraldes, University of Alberta
 
Learning Objectives:
1. Understand the current accepted
    indications for TIPS
2. Understand how to balance the risks
    and benefits of TIPS insertion
3. Optimize patient selection for TIPS
 
 
 

 
Cynthia Tsien, University Health Network
 
Learning Objectives:
1. Identify reasons for hospital admission in
    cirrhosis.
2. Describe system level interventions for
    prevention of admissions of cirrhotics.
3. Appreciate the benefits of preventing
    cirrhosis admissions.
 
 


Christopher Rose, Université de Montréal
 
Learning Objectives:
1. Understand the underlying
    hepatic encephalopathy
2. Appreciate the evidence of irreversible
    brain injury in hepatic encephalopathy
3. Realize the urgency of treating hepatic
    encephalopathy for a better life for
    patients and their families.
 

MORNING CONCURRENT SESSIONS - part 1

TIME
Public Health and Epidemiology Program
BALLROOM A

Basic Science Program
BALLROOM B

8:00 - 9:15 am
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 Co-Chairs: Lisa Barrett & Genevieve Huard
 
8:00 AM - 8:25 AM -
Delivering HCV care to PWID: We know that DAA
therapies are effective, now what?

Jason Grebely, Kirby Institute & University
of New South Wales

 
Learning Objectives:
1. Comprehend outcomes following DAA therapy
   among people receiving OST and people with recent
   injecting drug use
2. Understand key strategies to enhance HCV
    testing and linkage to HCV care for people who
    inject drugs
3. Recognize remaining challenges for enhancing HCV
    testing, linkage to care, and treatment among
    people who inject drugs.
 
8:25 - 8:50 am -
Epidemiology of Liver Disease in Canada
Jennifer Flemming, Queen's University
 
Learning Objectives in Development
 
8:50 - 9:15 am -
The Cascade of HCV Care
Naveed Janjua, Univeristy of British Columbia
 
Learning Objectives in Development
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 Co-Chairs: Jordan Feld & Sonya McParland
 
8:00 - 8:15 am -
Mechanisms of Liver Cell Death
Gregory Gores, Mayo Clinic
 
Learning Objectives:
1. Describe the different modes of cell death
2. Explain how cell death and non-lethal injury promote
    inflammation
 
8:15 - 8:45 am -
Fibrosis and HCC Progression
Naglaa Shoukry, Université de Montréal
 
Learning Objectives:
1. Describe, in basic terms, the role of type III
    inflammation and cytokines in influencing liver
    fibrosis progression at the molecular and cellular
    level
2. Obtain novel insights and knowledge about data
    from our group mapping the immune landscape of
    fibrotic livers and livers with HCC using cutting-edge
    microscopy techniques
 
8:30 - 8:45 am -
Host-Virus Interaction in HCV Infection
Selena Sagan, McGill University
 
Learning Objectives:
1. Explain the role of microRNAs in the Hepatitis C virus
    (HCV) life cycle
2. Describe one or more mechanisms by which miR-122
    promotes HCV accumulation
 
8:45 - 9:00 am -
Basic Science Approaches to Treating Inherited
Biliary

Anand Ghanekar, University of Toronto
 
Learning Objectives in Development
 
9:00 - 9:15 am -
Discussion and Q&A
 

MORNING CONCURRENT SESSIONS - part 2

TIME
Nursing Program
KINGSWAY ROOM

Viral Hepatitis Paper Session
BALLROOM B

9:15 - 10:00 am
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 Co-Chair: Kathy Poldre
 
Public Health and Harm Reduction Responses to the
Overdose Crisis

Mark Tyndall, UBC Centre for Disease Control
 
Learning Objectives:
1. Better comprehend the drivers behind the current
   overdose crisis
2. Explain when to consider overdose response
    interventions that go beyond standard harm
    reduction approaches
3. Explicate where there are linkages between
   overlapping challenges of
   HIV/HCV/poverty/stigma/overdose
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 Co-Chairs: Gisela Macphail & Ed Tam
 
Session Learning Objectives:
1.  Review data suggesting a definition for the mechanisms
        associated with CD4 T cell exhaustion in chronic HBV
        patients
2.  Describe how CD8+T-cell dysfunction in chronic HCV
        infection may be affected by an altered M1 macrophage
        phenotype
3.  Characterize the epidemiology, HBV status and antiviral
         treatment regimen in hepatitis B patients across Canada
4.  Review data on the effectiveness of direct acting
         antiviral agents (DAA) among people who inject drugs,
          in order to understand the extent to which treatments
          targeted at this population may reduce the overall HCV
          burden.
 
9:15 - 9:25 am -
Monocyte Exposure to HBV Antigens Leads to
Activation of HBV-specific CD4 T Cells

Aman Mehrotra, University Health Network
 
9:25 - 9:35 am -
Altered M1 Macrophage Phenotype May Contribute
to CD8+T-cell Dysfunction in Chronic HCV
Infection with Advanced Liver Fibrosis
Angela Crawley, Universiy Health Network
 
9:35 - 9:45 am -
A Retrospective Nationwide Study on Hepatitis B
Epidemiology and Genotypes; The Canadian
Hepatitis B Network
Carla Coffin, University of Calgary
 
9:45 - 9:55 am -
Real-World Effectiveness of Sofosbuvir-based
Regimens for Hepatitis C Treatment Among People
who Inject Drugs and those in Opiod Substitution
Therapy in Canada

Naveed Janjua, University of British Columbia
 

    MEETING ROOM
     
10:00 - 10:30 am Coffee Break
ONTARIO/NIAGARA
     
10:30 - 12:00 pm
 
 
 
 
 
 
Plenary Session #1: The Forgotten Hepatitides
Co-Chairs: Meredith Borman & Alnoor Ramji
 
Session Learning Objectives:
1.  Describe the changing understanding of Hepatitis D and E
2.  Understand the evolving research on treatment of Hepatitis D and E
3.  Optimally approach pregnant women with Hepatitis B.
BALLROOM A & B
 
 
 
 
 
10:30 am - 10:55 am Hepatitis E Update
  Heiner Wedemeyer, Hannover Medical School
 
Learning Objectives in Development
   
10:55 am - 11:00 am Q&A with Heiner Wedemeyer
   
11:00 am - 11:25 am Delta Hepatitis Update
  Theo Heller, University of Maryland
 
Learning Objectives in Development
   
11:25 am - 11:30 am Q&A with Theo Heller
   
11:30 am - 11:55 am Hep B and Pregnancy Update
  Carla Coffin, University of Calgary
 
Learning Objectives in Development
1. To explain the issues regarding HBV natural history in pregnancy and prevention of mother to child
    transmission
2. To review evidence for initiating HBV therapy in pregnancy
3. To review recommendations for monitoring and how to address post-partum HBV flares in
    treated and untreated patients
   
11:55 am - 12:00 pm Q&A with Carla Coffin
    MEETING ROOM
     
12:00 - 1:30 pm Lunch & Poster Sessions
ONTARIO/NIAGARA

AFTERNOON CONCURRENT SESSIONS - part 1

TIME
Public Health Epidemiology Program (Part 1) -
What is required to achieve elimination of Hepatitis C Infection in Canada by 2030?
BALLROOM A

Community Liver Update (Part 1) -
Best of AASLD
BALLROOM B

1:30 - 3:00 pm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 Co-Chairs: Jason Grebely & Naveed Janjua
 
Session Learning Objectives:
1.  Understand successful strategies that have been
        employed internationally to work towards achieving the
        WHO global HCV elimination targets
2. Understand ongoing initiatives to develop provincial
        or national frameworks to address HCV infection
        in Canada
3. Discuss potential goals, strategies, and targets which
        would be important to include in a national HCV plan to
        work towards HCV elimination
 
1:30 - 2:00 pm -
Achieving the WHO Hepatitis C Elimination Targets
by 2030: What is and is not working globally?

Jeffrey Lazarus, University of Copenhagen
 
2:00 - 2:10 pm -
Elimination of Hepatitis C Infection in Australia:
Successes and challenges
Jason Grebely, Kirby Institute & University of  New South Wales
 
2:10 - 2:20 pm -
Elimination of Hepatitis C Infection in Portugal:
Successes and challenges
Ricardo Baptista Leite, Member of Parliament, Lisbon,
Portugal

 
2:20 - 2:35 pm -
Elimination of Hepatitis C Infection in Canada:
Successes and chanllenges

Naveed Janjua, University of British Columbia
 
2:35 - 3:00 pm -
Panel Discussion and Questions


  Co-Chairs: Jordan Feld & Sonya McParland

 
Session Learning Objectives:
1. Describe research advances in Fatty Liver, Hepatitis C
    and General Hepatology.
2. Apply recent research advances to your own practice.
 
1:30 - 1:55 pm -
Viral Hepatitis Debrief
Paul Kwo, Stanford University
 
Learning Objectives in Development
 
1:55 - 2:00 pm -
Q&A with Paul Kwo
 
2:00 - 2:25 pm -
NAFLD Debrief
Kymberly Watt, Mayo Clinic
 
Learning Objectives:
1. Be familiar with the latest data and abstract review
    from the AASLD meeting meeting in October 2017
    level
2. Understand the multifactorial approach needed to
    manage the patient with NASH
 
2:25 - 2:30 pm -
Q&A with Kymberley Watt
 
2:30 - 2:55 pm -
General Hepatology Debrief
Michael Lucey, University of Wisconsin
 
Learning Objections in Development
 
2:55 - 3:00 pm -
Q&A with Michael Lucey
 


    MEETING ROOM
     
3:00 - 3:30 pm Coffee Break
ONTARIO/NIAGARA

AFTERNOON CONCURRENT SESSIONS - part 2

TIME
Public Health Epidemiology Program (part 2) -
What is Required to Acheive Elimination of Hepatitis C
Infection in Canada by 2030?
BALLROOM A
Community Liver Update (Part 2) -
Hot Topics
BALLROOM B

CAHN Programming -
KINGSWAY ROOM
3:30 - 5:00 pm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 Co-Chairs: Jason Grebely & Naveed Janjua
 
3:30 - 3:45 pm -
Strategy for the Elimination of Hepatitis
C in the United States: What was the
process and lessons learned?

Andrew Aronsohn - University of Chicago
     Medical Cente

 
3:45 - 4:00 pm -
A strategy to address hepatitis C
infection in British Columbia: What was
the process and where are we now?

Gina McGwan - British Columbia Ministry
of Health

 
4:00 - 4:15 pm -
What are the research gaps to monitor
and evaluate the elimination of hepatitis
C in Canada by 2030

Alison Marshall - Canadian Network on
Hepatitis C (CanHepC) and The Kirby
Institute, UNSW Sydney

 
4:15 - 5:00 pm -
What are the targets, goals, and actions
that would be required to achieve the
WHO hepatitis C elimination targets in
Canada by 2030?

Group Discussion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 Co-Chairs: Jeffrey So & Cynthia Tsien
 
Session Learning Objectives:
1.  Understand the best management of
         liver modules.
2.  Appreciate advances in the
         management of PBC and PSC.
3.  Describe optimal management of
         Alcoholic Hepatitis.
 
3:30 - 3:55 pm -
Management of Alcoholic Hepatitis
Keyur Patel, University of Toronto
     Medical Cente

 
Learning Objectives in Development
 
3:30 - 3:55 pm -
Q&A with Keyur Patel
 
4:00 - 4:25 pm -
Liver Masses: Benign and Malignant
David Wong, University Health Network
 
Learning Objectives in Development
 
4:25 - 4:30 pm -
Q&A
 
4:30 - 4:55 pm -
Update on PBC and PSC
Michael Trauner, Medical University
of Vienna
 
Learning Objectives in Development
 
4:55 - 5:00 pm -
Q&A with Michael Trauner
 
 
 
 
 
 
 
 
 
 

 

 Chair: Cheryl Dale
 
3:30 - 3:55 pm -
FibroScan: to CAP or not to CAP
Magdy Elkashab, Corporation for National
and Community Service

 
Learning Objectives in Development
1.  Identify validity of fibroscan in diagnosis
    and prediction of of prognosis in variety
    of liver disease, particularly NAFLD
2.  Appreciate the importance of CAP in
    patients with NAFLD
3.  understand validity of CAP in patients
    with various liver diseases other
   than NAFLD
 
3:55 - 4:00 pm -
Q&A with Magdy Elkashab
 
4:00 - 4:25 pm -
Hepatitis C: SVR and Beyond
Samuel Lee, University of Calgary
 
Learning Objectives:
1. Understand the significance of SVR in
   Hepatitis C Treatment
2. Discuss the Longterm Implications of
    Virological Cure on Disease Progression
    or Regression
 
4:25 - 4:30 pm -
Q&A with Samuel Lee
 
4:30 - 4:55 pm -
Sleep Wake Disturbances in Cirrhosis
Raed Hawa, University of Toronto
 
Learning Objectives in Development
1.  Develop a better understanding of the
    nature of sleep wake disturbances in
    patients with cirrhosis
2.  Increase their comfort with the
    diagnosis and management of these
    common complaints
 
4:55 - 5:00 pm -
Q&A with Raed Hawa

    MEETING ROOM
     
5:00 - 6:30 pm CASL Annual General Meeting
BALLROOM B
SUNDAY, FEBRUARY 11, 2018
CANADIAN LIVER MEETING - GENERAL HEPATOLOGY SESSIONS
    MEETING ROOM
     
7:00 - 1:00 pm Registration Open
BALLROOM FOYER
     
7:15 - 9:00 am CAHN Annual General Meeting
BALLROOM A
     
8:00 - 8:50 am
 
General Hepatology Paper Session
Co-Chairs: Harry Janssen & Giada Sebastiani
 
Session Learning Objectives:
1. Explain the role that visceral adiposity may play as a risk factor for HCC in male patients
   with cirrhosis
2. Describe how serological markers may be useful in identifying patients with PBC-AIH
    overlap syndrome
3. Review the results of a large-scale screening program evaluating the prevalence, predictors
    and evolution of preclinical compensated cirrhosis in a large cohort of HIV-infected patients
4. Examine the relationship between obesity and mortality in cirrhotic patients admitted to the
    intensive care unity with septic shock
5. Evaluate data on glutamine synthetase (GS) expression in endothelial cells of the
    blood-brain barrier
BALLROOM A
 
8:05 - 8:15 am
 
Visceral Adiposity Increases Risk for Hepatocellular Carcinoma in Male Patients with Cirrhosis and Recurrence after Liver Transplant
  Aldo Montano-Loza, University of Alberta
   
8:15 am - 8:20 am Evaluation of Various Novel Serological Biomarkers for the Identification of Patients with Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Overlap Syndrome
  Henry Hguyen, University of Calgary
   
8:20 am - 8:30 am
 
Occult Liver Cirrhosis Diagnosed by Transient Elastography is Frequent and Under-monitored in HIV-Infected Patients: results of a large-scale screening program
  Giada Sebastiani, McGill University
   
8:30 am - 8:40 am The Impact of Obesity in Cirrhotic Patients with Septic Shock: a retrospective cohort study
  Beverley Kok, University of Alberta
   
8:40 am - 8:50 am
 
Glutamine synthetase in the blood-brain barrier: targeting endothelial cells for the treatment of hepatic encephalopathy?
  Mariana Oliveira, Hepato-neuro lab, Centre de Recherche du Centre Hospitalier de l’Université de Montréal
    MEETING ROOM
     
9:00 - 9:45 am
 
 
 
 
 
 
CASL-CLF Gold Medal Lecture - Hepatocellular Carcinoma: Lessons Learned
Speaker: Gregory Gores, Mayo Clinic
 
Learning Objectives:
1.  Understand the clinical risk factors for developing hepatocellular carcinoma
2. Understand the genetic heterogeneity driving hepatocellular carcinogenesis
3. Understand the emerging treatment approaches for hepatocellular carcinoma
BALLROOM B
 
 
 
 
 
 
     
9:45 - 10:00 am
 
CASL Awards Ceremony
Co-Chairs: Harry Janssen & Giada Sebastiani
BALLROOM B
 
     
10:00 - 10:30 am Coffee Break
ONTARIO/NIAGARA
 

MORNING CONCURRENT SESSIONS - part 1

TIME
CAHN Case Studies
BALLROOM A

Liver Transplant Symposium
BALLROOM B

10:30 am - 12:00 pm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 Chair: Colina Yim
 
10:30 - 10:55 am -
Case Study #1: Addition Case
Lesley Gallagher, University of Copenhagen
 
Learning Objectives in Development
 
10:55 - 11:00 am -
Q&A with Lesley Gallagher
 
11:00 - 11:25 am -
Case Study #2 - Decompensated Cirrhosis: to
treat or not to treat

Liza Abraham, St. Michael's Hospital
 
Learning Objectives:
1. Understand how decompensated cirrhosis can have
    major implications regarding management and
    prevention of cirrhosis-related complications
2. Know when to consider a referral for liver
    transplantation evaluation
 
11:25 - 11:30 am -
Q&A with Liza Abraham
 
11:30 - 11:55 am -
Case Study #3: Mission Impossible: The challenges
faced while waiting for double transplant and a HCV
Treatment

Maria Stavrakis, Montreal Jewish General Hospital
 
Learning Objectives in Development
 
11:55 am - 12:00 pm -
Q&A with Maria Stavrakis

 
 
 
 
 
 


  Co-Chairs: Jordan Feld & Sonya McParland

 
10:30 - 10:55 am -
Transplant for Metabolic Liver disease (peds)
Steve Martin, University of Calgary
 
Learning Objectives:
1. Provide an overview of transplant approaches to
    treating metabolic diseases. (MLD)
2. Briefly describe experience with liver cell
    transplant in metabolic liver disease.
3. Understand the current role for gene therapy in MLD

10:55 - 11:00 am -
 Q&A with Steve Martin
 
11:00 - 11:25 am -
Long-term Care of Transplant Recipient
Kymberly Watt, Mayo Clinic
 
Learning Objectives:
1. Identify the leading causes of death in the long term
    followup of the liver transplant recipient
2. Consider the screening and prevention of metabolic
    and malignant comorbidities after liver transplant
 
11:25 - 11:30 am -
Q&A with Kymberley Watt
 
11:30 - 11:55 am -
Transplantation for Alcoholic Hepatitis
Michael Lucey, University of Wisconsin
 
Learning Objections in Development
 
11:55 am - 12:00 pm -
Q&A with Michael Lucey
 

    MEETING ROOM
     
12:00 - 1:30 pm Lunch & Poster Sessions
ONTARIO/NIAGARA
     
1:30 - 3:00 pm
 
 
Autoimmune Liver Disease Symposium
Co-Chairs: Aliya Gulamhusein & Andrew Mason
 
BALLROOM B
 
 
1:30 - 1:55 pm IgG4-Related Disease
  Bertus Eksteen, University of Calgary
 
Learning Objectives in Development
   
1:55 - 2:00 pm Q&A with Bertus Eksteen
   
2:00 - 2:25 pm Recurrance of PBC, PSC and AIH after Transplant
  Eric Yoshida, University of British Columbia
 
Learning Objectives:
1. Be aware of the clinical features of recurrent post-transplant primary sclerosing
   cholangitis, primary biliary cholangitis and autoimmine hepatitis
2. Be aware of natural history and potential treatment options
   
2:25 - 2:30 pm Q&A with Eric Yoshida
   
2:30 - 3:00 pm Is PBC an Autoimmune Disease? (Debate)
  Andrew Mason, University of Alberta & Michael Trauner, Medical University of Vienna
 
Learning Objectives in Development
1. Understand why patients with PBC make autoimmune responses and develop immune destruction of
    interlobular bile ducts
2. Appreciate that PBC is a complex interlobular bile ducts, disease with genetic, environmental, gender
    specific and even racial influences
3. Gain knowledge as to why autoimmunity is assumed to cause the biliary disease but other factors play role
   
    MEETING ROOM
     
2:30 - 3:00 pm Coffee Break
ONTARIO/NIAGARA
     
3:00 - 4:00 pm
 
 
 
 
 
 
KEEPING UP WITH THE LITERATURE
Co-Chairs: Mamatha Bhat & Erin Kelly

Session Learning Objectives:
1.  Describe the most impactful literature in GI, GIM and Hepatology in 2017
2.  Identify opportunities for integrating new knowledge into your own practice.
 
BALLROOM B
 
 
 
 

 
3:30 - 3:55 pm Top 3 Papers of 2017 - (Liver)
  Samuel Lee, University of Calgary
 
Learning Objectives:
1. Understand the Significance of 3 Important Hepatology Papers Published in 2017
2. Discuss how the Results of these Papers May Affect my Practice
   
3:55 - 4:00 pm Q&A with Samuel Lee
   
4:00 - 4:25 pm Top 3 Papers of 2017 (GI)
  Robert Bailey, University of Alberta
 
Learning Objectives in Development
   
4:25 - 4:30 pm Q&A with Robert Bailey
   
4:30 - 4:55 pm Top 3 Papers of 2017 (GIM)
  Speaker TBC
 
Learning Objectives in Development
   
4:55 - 5:00 pm Q&A